Safety of green tea extracts : a systematic review by the US Pharmacopeia
- PMID: 18484782
- DOI: 10.2165/00002018-200831060-00003
Safety of green tea extracts : a systematic review by the US Pharmacopeia
Abstract
Green tea [Camellia sinensis (L.) Kuntze] is the fourth most commonly used dietary supplement in the US. Recently, regulatory agencies in France and Spain suspended market authorization of a weight-loss product containing green tea extract because of hepatotoxicity concerns. This was followed by publication of adverse event case reports involving green tea products. In response, the US Pharmacopeia (USP) Dietary Supplement Information Expert Committee (DSI EC) systematically reviewed the safety information for green tea products in order to re-evaluate the current safety class to which these products are assigned. DSI EC searched PubMed (January 1966-June 2007) and EMBASE (January 1988-June 2007) for clinical case reports and animal pharmacological or toxicological information. Reports were also obtained from a diverse range of other sources, including published reviews, the US FDA MedWatch programme, USP's MEDMARX adverse event reporting system, the Australian Therapeutic Goods Administration, the UK Medicines and Healthcare products Regulatory Agency, and Health Canada's Canadian Adverse Drug Reaction Monitoring Program. Case reports pertaining to liver damage were evaluated according to the Naranjo causality algorithm scale. In addition, the Committee analysed information concerning historical use, regulatory status, and current extent of use of green tea products. A total of 216 case reports on green tea products were analysed, including 34 reports concerning liver damage. Twenty-seven reports pertaining to liver damage were categorized as possible causality and seven as probable causality. Clinical pharmacokinetic and animal toxicological information indicated that consumption of green tea concentrated extracts on an empty stomach is more likely to lead to adverse effects than consumption in the fed state. Based on this safety review, the DSI EC determined that when dietary supplement products containing green tea extracts are used and formulated appropriately the Committee is unaware of significant safety issues that would prohibit monograph development, provided a caution statement is included in the labelling section. Following this decision, USP's DSI ECs may develop monographs for green tea extracts, and USP may offer its verification programmes related to that dietary ingredient.
Similar articles
-
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts.Toxicol Rep. 2020 Feb 15;7:386-402. doi: 10.1016/j.toxrep.2020.02.008. eCollection 2020. Toxicol Rep. 2020. PMID: 32140423 Free PMC article. Review.
-
Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements.Toxicol Lett. 2017 Aug 5;277:104-108. doi: 10.1016/j.toxlet.2017.06.008. Epub 2017 Jun 24. Toxicol Lett. 2017. PMID: 28655517 Review.
-
United States pharmacopeia safety evaluation of spirulina.Crit Rev Food Sci Nutr. 2011 Aug;51(7):593-604. doi: 10.1080/10408391003721719. Crit Rev Food Sci Nutr. 2011. PMID: 21793723 Review.
-
The state of dietary supplement adverse event reporting in the United States.Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):962-70. doi: 10.1002/pds.1627. Pharmacoepidemiol Drug Saf. 2008. PMID: 18613260 Review.
-
United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.Menopause. 2008 Jul-Aug;15(4 Pt 1):628-38. doi: 10.1097/gme.0b013e31816054bf. Menopause. 2008. PMID: 18340277 Review.
Cited by
-
Potential therapeutic effects of green tea (Camellia sinensis) in eye diseases, a review.Heliyon. 2024 Mar 27;10(7):e28829. doi: 10.1016/j.heliyon.2024.e28829. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38601618 Free PMC article. Review.
-
Tea consumption and risk of bone health: an updated systematic review and meta-analysis.J Bone Miner Metab. 2024 Jan;42(1):99-114. doi: 10.1007/s00774-023-01479-y. Epub 2023 Dec 6. J Bone Miner Metab. 2024. PMID: 38057603
-
Cancer Metabolism as a Therapeutic Target and Review of Interventions.Nutrients. 2023 Oct 1;15(19):4245. doi: 10.3390/nu15194245. Nutrients. 2023. PMID: 37836529 Free PMC article. Review.
-
Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation.Am J Cancer Res. 2023 Apr 15;13(4):1407-1424. eCollection 2023. Am J Cancer Res. 2023. PMID: 37168333 Free PMC article.
-
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women.Nutrients. 2023 Jan 9;15(2):320. doi: 10.3390/nu15020320. Nutrients. 2023. PMID: 36678191 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources